Sphere Bio Company Profile

Background

Sphere Bio, formerly known as Sphere Fluidics, is a Cambridge, UK-based life sciences company specializing in single-cell analysis and isolation technologies. Established in 2010 as a spin-out from the University of Cambridge, the company has evolved from a droplet-based microfluidics innovator to a commercial provider of integrated life sciences tools and solutions. Sphere Bio's mission is to empower researchers by providing advanced platforms that streamline workflows in biotherapeutic discovery, cell therapy, and synthetic biology. The company's vision is to accelerate scientific discovery through innovation in single-cell analysis.

Key Strategic Focus

Sphere Bio focuses on developing and commercializing picodroplet-based microfluidic platforms designed for high-throughput single-cell screening and isolation. Their core objectives include enhancing the efficiency and precision of single-cell functional analysis workflows, thereby reducing project timelines from months to weeks. The company's primary markets encompass biopharmaceutical discovery and development, cell therapy engineering, bioproduction, and synthetic biology.

Financials and Funding

As of 2021, Sphere Bio has raised approximately £46.7 million through various funding rounds, loans, and grants. In November 2021, the company secured a $40 million funding round led by Sofinnova Partners and Redmile Group. The capital is intended to support the expansion of their product portfolio and global market presence.

Pipeline Development

Sphere Bio's flagship product is the Cyto-Mine® platform, an integrated device that automates single-cell analysis, sorting, imaging, and dispensing into individual wells of microtiter plates. This technology aids in the development of biotherapeutics for treating cancer, inflammatory diseases, and vaccine generation. In 2025, the company launched the next-generation Cyto-Mine® Chroma platform, designed to maximize the efficiency and precision of single-cell functional analysis workflows.

Technological Platform and Innovation

Sphere Bio's proprietary picodroplet microfluidic technology is central to their platforms. This technology enables the encapsulation and analysis of single cells within picodroplets, maintaining cell viability and allowing for high-throughput functional analysis. The company's solutions are designed to streamline workflows in biotherapeutic discovery and development, cell therapy, and synthetic biology.

Leadership Team

Ken Hitchner, MBA: Chairman of the Board of Directors. With over 30 years in the healthcare industry, Ken brings extensive strategic advisory and transactional expertise.

Dale Levitzke, BSc: Chief Executive Officer. Dale has over 25 years of experience in the life science tools, biopharma, and biotechnology industries, focusing on driving innovation and commercial growth.

Richard Hammond, MA MEng: Chief Technical Officer. Richard oversees R&D at Sphere Bio, bringing over 20 years of experience in developing healthcare and life sciences products.

Graeme Daniels, PhD: Vice-President of Commercial (EMEA). Graeme has over 20 years of experience in life science and biotechnology commercial roles, leading international sales and marketing strategies.

Jay Gerlach: Vice-President of Marketing. Jay brings over 20 years of experience in developing and commercializing innovative, microfluidics-based products for research and clinical applications.

Denise Emsden, FCIPD NEBOSH: Vice-President of People and Organizational Development. Denise has over 20 years of experience in organizational development and human resources management.

Andy Earp, MA Econ ACCA: Director of Finance. Andy is a Chartered Accountant with approximately 15 years of post-qualified experience, responsible for financial management and reporting.

Rob Treanor, BA: Vice-President of Operations. Rob oversees manufacturing, supply chain, quality, and facilities at Sphere Bio.

Erroll Rueckert: Commercial Director (North America). Erroll has over a decade of commercial experience in the life sciences industry, specializing in genomics and single-cell technologies.

Caroline Falzone: Director of Global Sales Operations & Consumables. Caroline has over a decade of experience in sales leadership and operational excellence within the life sciences and technology sectors.

Jay Manikandan: Vice-President of Commercial (APAC). Jay is a seasoned leader in life sciences commercial operations, driving market success for single-cell and multi-omics technologies across APAC.

Professor Wilhelm Huck, PhD: Co-Founder and Scientific Advisor. Wilhelm is a professor at Radboud University, focusing on complex molecular systems and single-cell studies.

Sharrol Bachas, PhD: Scientific Advisor. Sharrol is a biochemist and structural biologist with expertise in antibody engineering and high-throughput screening technologies.

Leadership Changes

In April 2024, Sphere Bio appointed Dale Levitzke as Chief Executive Officer. Dale brings over 25 years of experience in the life science tools, biopharma, and biotechnology industries, focusing on driving innovation and commercial growth.

Competitor Profile

Market Insights and Dynamics

The single-cell analysis market is experiencing significant growth, driven by advancements in biopharmaceutical research, cell therapy, and synthetic biology. The demand for high-throughput, precise, and efficient single-cell analysis technologies is increasing, positioning companies like Sphere Bio at the forefront of this expanding market.

Competitor Analysis

Key competitors in the single-cell analysis and microfluidics space include:

10x Genomics: Specializes in single-cell and spatial genomics technologies, offering platforms for high-throughput single-cell analysis.

Fluidigm Corporation: Provides microfluidic-based technologies for single-cell genomics and proteomics applications.

Berkeley Lights: Focuses on single-cell manipulation and analysis platforms, particularly for antibody discovery and cell line development.

These companies offer various technologies and platforms that compete with Sphere Bio's offerings in the single-cell analysis market.

Strategic Collaborations and Partnerships

Sphere Bio has established significant collaborations to strengthen its market position and expand capabilities:

APAC Distribution Network Expansion: In April 2025, Sphere Bio expanded its APAC distributor network, partnering with five new distributors across key Asian and Pacific markets, including 1st PhileKorea (South Korea), AS ONE Corporation (Japan), Decode Science (Australia and New Zealand), Everlife Research Instruments (Singapore), and Premas Life Sciences (India and Bangladesh). This expansion enhances regional access to Sphere Bio's technologies and support.

China Operations Expansion: In June 2025, Sphere Bio appointed Redbert Biotechnology as its exclusive distribution partner in China and appointed Johnathan Fu as China Distribution Manager to lead regional partnerships and enhance customer support.

Operational Insights

Sphere Bio's strategic considerations include:

Market Position: Leveraging proprietary picodroplet microfluidic technology to offer high-throughput single-cell analysis solutions.

Competitive Advantages: Providing integrated platforms that streamline workflows, reduce project timelines, and maintain cell viability, distinguishing Sphere Bio from competitors.

Strategic Opportunities and Future Directions

Sphere Bio's strategic roadmap includes:

Product Portfolio Expansion: Continuing to develop and launch innovative platforms and assay kits to meet evolving research needs.

Global Market Penetration: Strengthening international presence through strategic partnerships and distributor networks, particularly in high-growth regions like APAC and China.